Cite
Szabo BG, Lorinczi C, Szanka J, et al. Simultaneous effective treatment of critical COVID-19 disease and newly diagnosed high-risk multiple myeloma with thalidomide, methylprednisolone, tocilizumab and baricitinib: is it clinically feasible?. Minerva Med. 2021;doi: 10.23736/S0026-4806.20.07050-0.
Szabo, B. G., Lorinczi, C., Szanka, J., Lakatos, B., Sinko, J., Szlavik, J., & Mikala, G. (2021). Simultaneous effective treatment of critical COVID-19 disease and newly diagnosed high-risk multiple myeloma with thalidomide, methylprednisolone, tocilizumab and baricitinib: is it clinically feasible?. Minerva medica, . https://doi.org/10.23736/S0026-4806.20.07050-0
Szabo, Balint G, et al. "Simultaneous effective treatment of critical COVID-19 disease and newly diagnosed high-risk multiple myeloma with thalidomide, methylprednisolone, tocilizumab and baricitinib: is it clinically feasible?." Minerva medica vol. (2021). doi: https://doi.org/10.23736/S0026-4806.20.07050-0
Szabo BG, Lorinczi C, Szanka J, Lakatos B, Sinko J, Szlavik J, Mikala G. Simultaneous effective treatment of critical COVID-19 disease and newly diagnosed high-risk multiple myeloma with thalidomide, methylprednisolone, tocilizumab and baricitinib: is it clinically feasible?. Minerva Med. 2021 Dec 03; doi: 10.23736/S0026-4806.20.07050-0. Epub 2021 Dec 03. PMID: 34856779.
Copy
Download .nbib